European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company formed to pursue a business combination with a target in the European biotechnology and life sciences sector. The SPAC completed its initial public offering in 2021 and is focused on identifying acquisition candidates operating within the European biotech ecosystem. An 8-K disclosure was filed with the SEC on October 17, 2022, under accession number 0000950103-22-017851, reflecting a reportable corporate event during the company's search phase. EBAC represents one of several life sciences-focused vehicles that emerged during the broader SPAC boom targeting cross-border healthcare innovation. For full filing history, timeline data, and deal status on EBAC, sign up for complete access at SpacDesk.